Abstract: The present invention relates to novel tetracyclic benzimidazole derivative compounds of the following formula:
wherein R1 to R10 have the meanings described in here.
The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing tetracyclic benzimidazole derivative compounds.
Abstract: Libraries of ethylenediamine compounds having the general formula (I):
wherein R1 to R6, m, n, o and p are as defined herein, are prepared using solid phase combinatorial chemistry techniques. A heterocyclic alcohol is reacted with an ethylenediamine bound to a solid support to give a scaffold having sites of diversity. Libraries of the invention are useful for screening in biological assays in order to identify pharmaceutically useful compounds.
Type:
Grant
Filed:
August 21, 1998
Date of Patent:
November 13, 2001
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Eric Edward Swayze, Elizabeth Anne Campbell Jefferson
Abstract: Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 23, 2001
Assignee:
NPS Pharmaceuticals, Inc.
Inventors:
Alan L. Mueller, Bradford C. VanWagenen, Eric G. DelMar, Manuel F. Balandrin, Scott T. Moe, Linda D. Artman
Abstract: Peptoid compounds of Formula I and Formula II are disclosed
The compounds are useful in the treatment of matrix metalloproteinase-mediated disorders.
Type:
Grant
Filed:
June 4, 1999
Date of Patent:
September 25, 2001
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Donald T. Witiak, Paul J. Bertics, Yingsheng Zhang
Abstract: Synthetic methods for solution and solid-phase synthesis of combinatorial libraries of dihydro-quinazolinones, including synthesis of 2,3-dihydro-3-alkoxy-4(1H)-quinazolinones or 2,3-dihydro-3-hydroxy-4(1H)-quinazolinones via the Lewis-acid catalyzed reaction of an appropriate 2-aminobenzamide with an aldehyde at ambient temperature performed on a solid support or in solution.
Abstract: The invention relates to the use of a compound selected from:
[&agr;-(tert-butylaminomethyl)-3,4-dichlorobenzyl]thioacetamide and its laevorotatory isomer,
[&agr;-(tert-amylaminomethyl)-3,4-dichlorobenzyl]thioacetamide and its isomers,
[&agr;-(1-adamantylaminomethyl)3,4-dichlorobenzyl]thioacetamide and its isomers, as well as the addition salts of these compounds with pharmaceutically acceptable acids, for inhibiting dopamine reuptake.
Abstract: The present invention provides an efficient and versatile method for the synthesis and screening of combinatorial libraries of benzimidazoles, benzoxazoles, benzothiazoles, and derivatives thereof. In order to expedite the synthesis of large arrays of compounds possessing these core structures, a general methodology for solid phase synthesis of these derivatives is provided. Arrays of benzimidazoles, benzoxazoles, benzothiazoles, and derivatives thereof useful as peptidomimetics and for the identification of agents having antifungal, antiviral, antimicrobial, anticoagulant, and antiulcer activity, or use in the treatment of inflammation, hypertension, cancer, and other conditions can be prepared by this method.
Abstract: Administration mediums comprising solutions of nitrous oxide in water, alcohols, ethers or oils, and optionally including essential fatty acids or C1-C6 alkyl esters thereof enhance the action of analgesic, anti-inflammatory and anti-pyretic drugs. The drugs may be combined with the medium into a pharmaceutical composition or may be taken orally by swallowing the drug with the aid of the medium.
Abstract: Imido and amido substituted alkanohydroxamic acids reduce the levels of TNF&agr; and inhibit phosphodiesterase in a mammal. A typical embodiment is 3-(3-cyclopentyloxy-4-methoxyphenyl)-N-hydroxy-3-phthalimidopropionamide.
Abstract: The power of citalopram, fluvoxamine and paroxetine to increase the availability of sarotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.
Abstract: A preventive and/or therapeutic medicament for circadian rhythm sleep disorders such as jet lag syndrome which comprises as an active ingredient an alkylenedioxybenzene derivative represented by the following formula (I) wherein m represent an integer of from 2 to 5, and n represents an integer of from 1 to 3, such as 5-[3-[(2S)-(1,4-benzodioxan-2-yl-methyl)amino]propoxy]-1,3-benzodioxol, or a pharmaceutically acceptable salt thereof.
Abstract: The present invention is directed to a sterile pharmaceutical composition comprising a propofol containing oil-in-water emulsion formulation having as an antimicrobial agent, a member selected from the group consisting of benzyl alcohol and sodium ethylene diamine tetraacetate; benzethonium chloride; and benzyl alcohol and sodium benzoate.
Type:
Grant
Filed:
July 15, 1999
Date of Patent:
October 31, 2000
Assignee:
Abbott Laboratories
Inventors:
Thomas May, John Hofstetter, Kathleen L. Olson, Sukumaran K. Menon, Bernard A. Mikrut, Clayton S. Ovenshire, Lawrence John Rhodes, Earl R. Speicher, James R. Waterson